R&D Systems Duoset Elisa Mcp-1

Lab Reagents

Duoset Elisa Laboratories manufactures the r&d systems duoset elisa mcp-1 reagents distributed by Genprice. The R&D Systems Duoset Elisa Mcp-1 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact duoset elisa. Other R&D products are available in stock. Specificity: R&D Category: Systems Group: Duoset Elisa

Duoset Elisa information

(R)-Lisofylline

C4158-1 1 mg
EUR 154.8
Description: Lisofylline (LSF) is a potent anti-inflammatory agent. LSF is a chiral metabolite of pentoxifylline. (R)-LSF is the biologically active isomer of LSF [1].

(R)-Lisofylline

C4158-10 10 mg
EUR 822
Description: Lisofylline (LSF) is a potent anti-inflammatory agent. LSF is a chiral metabolite of pentoxifylline. (R)-LSF is the biologically active isomer of LSF [1].

(R)-Lisofylline

C4158-5 5 mg
EUR 489.6
Description: Lisofylline (LSF) is a potent anti-inflammatory agent. LSF is a chiral metabolite of pentoxifylline. (R)-LSF is the biologically active isomer of LSF [1].

Granuliberin R

5-01251 4 x 5mg Ask for price

Ranatensin R

5-01868 4 x 1mg Ask for price

(R)-Crizotinib

A3020-10 10 mg
EUR 129.6
Description: Crizotinib is a potent, ATP-competitive, small-molecule and orally available inhibitor of c-Met kinase with a Ki value of 4 nmol/L[1].Crizotinib has shown to inhibit wild-type c-Met phosphorylation with a mean IC50 value of 11 nmol/L in multiple human endothelial and carcinoma cell lines.

(R)-Crizotinib

A3020-100 100 mg
EUR 254.4
Description: Crizotinib is a potent, ATP-competitive, small-molecule and orally available inhibitor of c-Met kinase with a Ki value of 4 nmol/L[1].Crizotinib has shown to inhibit wild-type c-Met phosphorylation with a mean IC50 value of 11 nmol/L in multiple human endothelial and carcinoma cell lines.

(R)-Crizotinib

A3020-5.1 10 mM (in 1mL DMSO)
EUR 164.4
Description: Crizotinib is a potent, ATP-competitive, small-molecule and orally available inhibitor of c-Met kinase with a Ki value of 4 nmol/L[1].Crizotinib has shown to inhibit wild-type c-Met phosphorylation with a mean IC50 value of 11 nmol/L in multiple human endothelial and carcinoma cell lines.

(R)-Crizotinib

A3020-50 50 mg
EUR 199.2
Description: Crizotinib is a potent, ATP-competitive, small-molecule and orally available inhibitor of c-Met kinase with a Ki value of 4 nmol/L[1].Crizotinib has shown to inhibit wild-type c-Met phosphorylation with a mean IC50 value of 11 nmol/L in multiple human endothelial and carcinoma cell lines.

(R)-Crizotinib

A3020-S Evaluation Sample
EUR 97.2
Description: Crizotinib is a potent, ATP-competitive, small-molecule and orally available inhibitor of c-Met kinase with a Ki value of 4 nmol/L[1].Crizotinib has shown to inhibit wild-type c-Met phosphorylation with a mean IC50 value of 11 nmol/L in multiple human endothelial and carcinoma cell lines.

R(-)-Gossypol

20-abx076641
  • EUR 427.20
  • EUR 1111.20
  • 10 mg
  • 50 mg

(R)-Methyglycidate

20-abx181457
  • EUR 326.40
  • EUR 1680.00
  • EUR 594.00
  • 1 g
  • 25 g
  • 5 g

(R)-(-)-Epichlorohydrin

abx182749-25g 25 g
EUR 243.6

R-(+)-Lansoprazole

20-abx186556
  • EUR 661.20
  • EUR 910.80
  • EUR 1446.00
  • 1 g
  • 2 g
  • 5 g

(R)-Bicalutamide

BC1004-050 50mg
EUR 230.4

(R)-Bicalutamide

BC1004-100 100mg
EUR 295.2

(R)-Bicalutamide

BC1004-250 250mg
EUR 472.8